TESARO (TSRO) Getting Positive Press Coverage, Analysis Finds
Headlines about TESARO (NASDAQ:TSRO) have trended positive recently, Accern reports. Accern ranks the sentiment of news coverage by monitoring more than twenty million blog and news sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. TESARO earned a daily sentiment score of 0.29 on Accern’s scale. Accern also assigned news headlines about the biopharmaceutical company an impact score of 45.6793983951242 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the near future.
These are some of the headlines that may have impacted Accern’s scoring:
- TESARO (TSRO) Ovarian Cancer Drug Zejula Gets Approval in EU – Nasdaq (nasdaq.com)
- TESARO Announces Participation in Two Investor Conferences – GlobeNewswire (press release) (globenewswire.com)
- TESARO : Announces European Commission Approval of ZEJULA for Women With Recurrent Ovarian Cancer (4-traders.com)
- TESARO Secures $500 Million Non-Dilutive Term Loan Financing (markets.financialcontent.com)
TESARO (NASDAQ:TSRO) traded down $1.19 on Thursday, reaching $83.91. The company had a trading volume of 708,300 shares, compared to its average volume of 1,029,724. TESARO has a twelve month low of $83.35 and a twelve month high of $192.94. The company has a quick ratio of 4.35, a current ratio of 4.73 and a debt-to-equity ratio of 0.34.
TESARO (NASDAQ:TSRO) last released its earnings results on Tuesday, November 7th. The biopharmaceutical company reported ($0.47) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.16) by $0.69. The firm had revenue of $142.77 million during the quarter, compared to the consensus estimate of $130.57 million. TESARO had a negative return on equity of 93.39% and a negative net margin of 251.22%. The company’s revenue was up 740.3% compared to the same quarter last year. During the same period in the prior year, the company posted ($1.72) EPS. research analysts expect that TESARO will post -8.16 EPS for the current fiscal year.
TSRO has been the subject of several research analyst reports. ValuEngine upgraded TESARO from a “sell” rating to a “hold” rating in a research note on Tuesday, August 1st. Morgan Stanley reiterated an “overweight” rating and set a $183.00 target price on shares of TESARO in a research note on Thursday, August 10th. Robert W. Baird reiterated a “neutral” rating and set a $140.00 target price (down from $155.00) on shares of TESARO in a research note on Thursday, August 10th. Evercore ISI initiated coverage on TESARO in a research note on Wednesday, August 16th. They set an “in-line” rating and a $121.00 target price for the company. Finally, Credit Suisse Group set a $190.00 target price on TESARO and gave the stock a “buy” rating in a research note on Friday, August 18th. Two equities research analysts have rated the stock with a sell rating, ten have issued a hold rating, fourteen have assigned a buy rating and one has issued a strong buy rating to the company. The stock has an average rating of “Buy” and a consensus target price of $161.72.
In other news, SVP Martin H. Jr. Huber sold 592 shares of the company’s stock in a transaction on Friday, September 22nd. The stock was sold at an average price of $118.60, for a total transaction of $70,211.20. Following the completion of the sale, the senior vice president now directly owns 6,943 shares in the company, valued at approximately $823,439.80. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, VP Grant C. Bogle sold 14,167 shares of the company’s stock in a transaction on Friday, September 1st. The shares were sold at an average price of $135.00, for a total value of $1,912,545.00. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 35,692 shares of company stock valued at $4,628,976. Corporate insiders own 40.50% of the company’s stock.
TESARO, Inc is an oncology-focused biopharmaceutical company. The Company operates through the business of developing and commercializing of oncology-focused therapeutics segment. It is developing oncology-related product candidates, including rolapitant, niraparib and the product candidates under its immuno-oncology platform.
Receive News & Ratings for TESARO Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TESARO Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.